EMvision Medical Devices (ASX:EMV) Accounts Receivable: A$5.75 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:EMV EMvision Medical Devices Ltd ASX:EMV
18 GF Score
Price A$1.77
! 3 Warning Signs
View Full Analysis

What is EMvision Medical Devices Accounts Receivable?

EMvision Medical Devices ASX:EMV +1.14% 18 Accounts Receivable is A$5.75 Mil as of Dec. 2025. GuruFocus rates ASX:EMV with a GF Score™ of 18/100. The stock has 3 warning signs investors should review.

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. EMvision Medical Devices's accounts receivables for the quarter that ended in Dec. 2025 was A$5.75 Mil.

Accounts receivable can be measured by Days Sales Outstanding.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. EMvision Medical Devices's Net-Net Working Capital per share for the quarter that ended in Dec. 2025 was A$0.18.

EMvision Medical Devices Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

EMvision Medical Devices's Days Sales Outstanding for the quarter that ended in Dec. 2025 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=5.746/0*91
=

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), EMvision Medical Devices's accounts receivable are only considered to be worth 75% of book value:

EMvision Medical Devices's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2025 is calculated as:

Net-Net Working Capital Per Share
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(17.56+0.75 * 5.746+0.5 * 0-5.203
-0-0)/92.939
=0.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

EMvision Medical Devices Accounts Receivable Related Terms

EMvision Medical Devices Accounts Receivable Historical Data

* Premium members only.

The historical data trend for EMvision Medical Devices's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

EMvision Medical Devices Accounts Receivable Chart

EMvision Medical Devices Annual Data
Trend Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Accounts Receivable
Get a 7-Day Free Trial 0.00 0.00 0.00 0.02 0.00

EMvision Medical Devices Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Accounts Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.02 0.06 0.00 5.75
ASX:EMV
18GF Score
EMvision Medical Devices Ltd ASX:EMV
Accounts Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

EMvision Medical Devices Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Frequently Asked Questions Learn more about Accounts Receivable →
What does a Accounts Receivable of A$5.75 Mil mean?
EMvision Medical Devices (ASX:EMV) has a Accounts Receivable of A$5.75 Mil as of Dec. 2025. Accounts receivable is the amount a company expects to receive from credit-extending customers. View historical data on EMvision Medical Devices and its competitors.
Is EMvision Medical Devices' Accounts Receivable too high?
EMvision Medical Devices' current Accounts Receivable is A$5.75 Mil. Overall, EMvision Medical Devices has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does EMvision Medical Devices' Accounts Receivable compare to ABT and SYK?
EMvision Medical Devices' Accounts Receivable of A$5.75 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Receivable for a Medical Devices & Instruments company?
A good Accounts Receivable depends on the Medical Devices & Instruments industry context. However, Accounts Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Receivable mean?
A high Accounts Receivable can signal that a stock is expensive relative to its fundamentals. Accounts receivable is the amount a company expects to receive from credit-extending customers. View historical data on EMvision Medical Devices and its competitors. EMvision Medical Devices's current Accounts Receivable is A$5.75 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EMvision Medical Devices stock overvalued right now?
EMvision Medical Devices (ASX:EMV) has a current Accounts Receivable of A$5.75 Mil. The current Accounts Receivable is A$5.75 Mil. EMvision Medical Devices' overall GF Score™ is 18/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Receivable calculated?
Accounts Receivable is calculated from a company's financial statements. For EMvision Medical Devices (ASX:EMV), the current Accounts Receivable is A$5.75 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

EMvision Medical Devices Business Description

Address 65 Epping Road, Suite 4.01, Macquarie Park, Sydney, NSW, AUS, 2113
EMvision Medical Devices Ltd is an Australian medical device company. The company is focused on the research and development, and commercialisation of neurodiagnostic technology for stroke diagnosis and monitoring, as well as other medical imaging needs. Its focus is portable, cost-effective, and non-invasive brain scanners, including a bedside device (emu) and an ultra-lightweight pre-hospital device (First Responder). Its first indication targets acute stroke care, with a second planned indication in traumatic brain injury.
18GF Score

Get the complete analysis for ASX:EMV

Accounts Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$1.77
Price